Related Experiment Video
Updated: Mar 26, 2026
06:46
Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
Published on: February 28, 2025
893
Caffeine Prevents Hyperoxia-Induced Functional and Structural Lung Damage in Preterm Rabbits
Taro Nagatomo1, Julio Jiménez, Jute Richter
1Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Neonatology
|February 12, 2016
Summary
Caffeine treatment in preterm rabbits improved lung function and reduced inflammation and structural damage caused by hyperoxia. This suggests caffeine may be a potential therapy for bronchopulmonary dysplasia in premature infants.
Area of Science:
- Neonatal Physiology
- Pulmonary Medicine
- Pharmacology
Background:
- Bronchopulmonary dysplasia (BPD) is a common complication in extremely preterm infants.
- Caffeine is a standard treatment for apnea of prematurity.
- Caffeine's potential benefits for BPD are under investigation.
Purpose of the Study:
- To investigate the effects of caffeine on inflammation, lung structure, and function in a rabbit model of BPD.
- To assess caffeine's efficacy in mitigating hyperoxia-induced lung injury.
Main Methods:
- Preterm rabbits were exposed to normoxia or hyperoxia, with or without caffeine.
- Lung function was measured using lung volume, tissue damping, elastance, and compliance.
- Airway and vascular morphometry were assessed.
- Lung tissue inflammation was scored.
Main Results:
- Caffeine significantly improved lung function, increasing lung volume and total lung capacity.
- Caffeine reduced tissue damping and elastance, while improving compliance.
- Histological analysis showed decreased alveolar size and inflammation with caffeine treatment.
- Radial alveolar counts were increased in the caffeine group.
Conclusions:
- Caffeine administration ameliorates functional, structural, and inflammatory pulmonary changes in preterm rabbits exposed to hyperoxia.
- These findings support caffeine as a potential therapeutic agent for preventing or treating bronchopulmonary dysplasia.
